Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04205812 · ClinicalTrials.gov registry record · Phase 3
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
A Phase 3 study of Metastatic Non-Squamous Non-Small Cell Lung Cancer and Metastatic Squamous Non-Small Cell Lung Cancer, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 583
- Enrollment target
- 20
- Study locations
NCT04205812: Active Phase 3 study of Metastatic Non-Squamous Non-Small Cell Lung Cancer and Metastatic Squamous Non-Small Cell Lung Cancer, sponsored by Incyte Corporation.
NCT04205812 is a Phase 3 study of Metastatic Non-Squamous Non-Small Cell Lung Cancer and Metastatic Squamous Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 583 participants, above the 127-participant average among 3 other Metastatic Non-Squamous Non-Small Cell Lung Cancer trials with a reported enrollment target (359% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04205812, a Phase 3 study of Metastatic Non-Squamous Non-Small Cell Lung Cancer and Metastatic Squamous Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 583 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
Primary Outcome
Overall survival was defined as the time between the date of randomization and the date of death due to any cause.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Retifanlimab
- DRUG Cisplatin
- DRUG Pemetrexed
Study Locations (20)
Other
- Fundacao Pio Xii Hospital de Cancer de Barretos - Barretos
- Incan - Instituto Do Cancer - Hospital Pompeia - Caxias do Sul
- Centro Regional Integrado de Oncologia - Fortaleza
- Oncosite - Centro de Pesquisa Clinica E Oncologia - Ijuí
- Clinica de Neoplasias Litoral Ltda - Itajaí
- Hospital Do Cancer de Londrina - Londrina
- Instituto Mederi de Pesquisa E Saude - Passo Fundo
- Hgb - Hospital Giovanni Battista - Mae de Deus Center - Porto Alegre
- Inca - Instituto Nacional de Cancer - Rio de Janeiro
- Sao Camilo Oncologia - S?O Paulo
- Cepho - Centro de Estudos E Pesquisas de Hematologia E Oncologia - Santo André
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto - São José
- Mc Women'S Health-Nadezhda Eood - Sofia
- Acibadem Cityclinica Mhat Tokuda - Sofia
- Umhat Sv. Ivan Rilski Ead - Sofia
- Mhat Serdika Eood - Sofia
- Multiprofile Hospital For Active Treatment Central Onco Hospital Ood - Sofia
California
- Pacific Cancer Medical Center - Anaheim
- Innovative Clinical Research Institute - Whittier
Pennsylvania
- Reading Hospital and Medical Center - Reading
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 583 participants |
| Start Date | 2020-09-11 |
| Est. Completion | 2026-08-28 |
| Phase | Phase 3 |
What the registry record for NCT04205812 still lists
NCT04205812 is an interventional study that assigns participants to a tested intervention. The registered 583 participants enrollment target is mid-sized for trials with a published cap, above the 127-participant average among 3 other Metastatic Non-Squamous Non-Small Cell Lung Cancer trials with a reported enrollment target (359% higher).
The record links to 2 conditions, with Metastatic Non-Squamous Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT04205812 names 20 study sites across 3 states, led by Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04205812 about?
NCT04205812 is a clinical study titled "Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer". The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
What is the current status of trial NCT04205812?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 583 participants. The study started on 2020-09-11. Estimated completion is 2026-08-28.
What conditions does trial NCT04205812 study?
This clinical trial studies the following conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04205812?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Retifanlimab (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT04205812?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04205812 being conducted?
This trial has 20 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non-Squamous Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
RECRUITING · Phase 2
-
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
RECRUITING · Phase 2
-
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03840083 · 584 participants · NA
Sleep-dependent Learning in Aging
- NCT04984291 · 584 participants · NA
Zimmer Biomet Shoulder Arthroplasty PMCF
- NCT05983757 · 584 participants · NA
Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe
- NCT06569290 · 584 participants · NA
Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Science-based Approaches
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI